Real-World Evidence Update on the Value of CGM

Long-Term Glycemic Control in T2D

Emerging evidence indicates that CGM use is associated with improvements in glycemic control in adults with noninsulin-treated T2D.

Key Takeaways Background Study Population Results

A1c Reduction in Managed Care

A growing body of evidence shows that CGM utilization improves glycemic outcomes in T2D, with associated reduction in health care resource utilization.

Key Takeaways Background Study Population Results

T2D Outcomes in the Community Setting

Access to CGM for people with T2D remains limited, especially for those treated in the primary care setting.

Key Takeaways Background Study Population Results

Cost-Effectiveness in T2D

In the United States, diabetes and its complications resulted in a total cost of $412.9 billion in 2022.

Key Takeaways Background Study Population Results

Reduced Hospitalizations in T2D

The rising prevalence of diabetes in the United States is contributing to substantially increasing healthcare resource utilization.

Key Takeaways Background Study Population Results

Subanalysis

Study Population Results